These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22579408)

  • 1. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
    Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
    Fukui T; Otani S; Hataishi R; Jiang SX; Nishii Y; Igawa S; Mitsufuji H; Kubota M; Katagiri M; Masuda N
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):803-6. PubMed ID: 20035424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
    Nakamichi S; Kubota K; Horinouchi H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Tamura T
    Jpn J Clin Oncol; 2013 Apr; 43(4):422-5. PubMed ID: 23410901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
    Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
    Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
    Tsubata Y; Hamada A; Sutani A; Isobe T
    J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
    ter Heine R; van den Bosch RT; Schaefer-Prokop CM; Lankheet NA; Beijnen JH; Staaks GH; van der Westerlaken MM; Malingré MM; van den Brand JJ
    Lung Cancer; 2012 Mar; 75(3):391-7. PubMed ID: 22101147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
    Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M
    Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
    Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
    Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H
    Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
    Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
    Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
    Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
    Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
    J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
    Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.